Predicting Prostate Cancer Progression During Active Surveillance Using Longitudinal bpMRI Scans and A Multi-scale Foundation Model

\mathbf{Y} ifan \mathbf{W} ang 1,4	WANGYFAN@UMICH.EDU
${f Bin}\;{f Lou}^1$	BIN.LOU@SIEMENS-HEALTHINEERS.COM
Heinrich von \mathbf{Busch}^2	HEINRICH.VON_BUSCH@SIEMENS-HEALTHINEERS.COM
${f Robert} \ {f Grimm}^2$	ROBERTGRIMM@SIEMENS-HEALTHINEERS.COM
Sanoj Punnen ³	S.PUNNEN@MED.MIAMI.EDU
$\mathbf{Dorin}\ \mathbf{Comaniciu}^1$	DORIN.COMANICIU@SIEMENS-HEALTHINEERS.COM
Ali Kamen 1	ALI.KAMEN@SIEMENS-HEALTHINEERS.COM
ProstateAI Clinical Collaborators*	

¹ Digital Technology and Innovation, Siemens Healthineers, Princeton, NJ, USA

² Diagnostic Imaging, Siemens Healthineers AG, Erlangen, Bavaria, Germany

³ University of Miami, Miller School of Medicine, Miami, FL, USA

⁴ University of Michigan, Electrical Engineering and Computer Science, Ann Arbor, MI, USA

Editors: Under Review for MIDL 2025

Abstract

Active Surveillance (AS) is the recommended management strategy for patients with lowor intermediate-risk Prostate Cancer (PCa), providing a safe alternative that helps avoid the adverse effects of overtreatment. While artificial intelligence (AI)-based models for PCa detection have been extensively studied, their application in AS remains challenging, with limited research addressing the detection of PCa progression in AS scenarios. In this study, we present a novel framework for predicting PCa progression within AS protocols using biparametric MRI (bpMRI). Due to the limited availability of longitudinal bpMRI scans (206 patients in our study), we first developed a multi-scale foundation model trained on a large cohort of single-year bpMRI scans, comprising 5,162 patients from 10 different institutions. Building on this foundation, we designed a three-module framework: (1) a lesion detection module to identify PCa lesions in full bpMRI scans, (2) a lesion classification module to perform detailed analysis of the identified lesion regions, and (3) a multi-scan lesion progression prediction module to assess changes in lesions over time using longitudinal bpMRI patches. The proposed framework was evaluated on a cohort from an AS clinical trial and demonstrated significant performance improvements over baseline models and radiologists, highlighting its potential to enhance clinical decision-making in AS management.

Keywords: Prostate Cancer Diagnosis, Active Surveillance, Foundation Model, Longitudinal bpMRI.

1. Introduction

Prostate cancer (PCa) is the second most commonly diagnosed cancer and the sixth leading cause of cancer-related deaths among men worldwide (Siegel et al., 2023). A substantial

^{*} A list of members and affiliations appears at the end of the paper

proportion of newly diagnosed cases involve patients with low- or intermediate-risk localized PCa, for whom curative treatments such as surgery or radiation offer limited benefits but carry a significant risk of adverse side effects (Michaelson et al., 2008). In clinical practice, Active Surveillance (AS) is widely recognized as a safe and effective alternative to immediate treatment (Kinsella et al., 2018; Dall'Era and Evans, 2012). Under AS protocols, radiologists monitor PCa progression through follow-up evaluations, including Prostate-Specific Antigen (PSA) tests and repeat prostate biopsies, with intervention considered only if progression is detected (Adamy et al., 2011; Tosoian et al., 2015). Recently, Magnetic Resonance Imaging (MRI) has gained prominence in AS protocols due to its potential to improve monitoring and reduce the need for invasive procedures such as biopsies. Nevertheless, standardized guidelines for its use in AS remain unclear (Baboudjian et al., 2022; Kinsella et al., 2018).

Currently, AI-driven models have demonstrated significant advantages in detecting and assessing PCa using MRI scans from a single time point (Yu et al., 2020b; De Vente et al., 2020). However, relatively few studies have explored methods for detecting PCa progression in AS scenarios (Jones et al., 2021; Bozgo et al., 2024). Existing progression calculators based on clinical test results have shown moderate performance (Tomer et al., 2021; Lee et al., 2022), but they often fail to fully utilize the rich information available in MRI data. Deep learning-based approaches leveraging model-extracted features have shown improved capabilities, but most are limited to single-year MRI examinations (Sushentsev et al., 2021). For patients in AS, where the primary goal is to detect histological biopsy upgrading of a candidate lesion, a single-year MRI scan may not provide sufficient information. Some deep learning models have attempted to combine baseline and follow-up MRI exams to identify PCa progression (Sushentsev et al., 2021, 2023). However, the limited availability of datasets containing longitudinal MRI scans for individual patients often restricts these methods to small models with constrained feature spaces, focusing on patient-level diagnosis rather than identifying which specific lesion has progressed. In the deep learning domain, building foundation models trained on large-scale medical imaging datasets using self-supervised learning (He et al., 2022) has emerged as a promising solution to address the challenges posed by limited datasets. These models can then be fine-tuned for downstream tasks. To the best of our knowledge, this approach has not yet been explored for detecting PCa progression in patients undergoing AS.

Building on the strengths of previous studies while addressing their limitations, we propose an end-to-end PCa progression prediction framework for AS protocols using biparametric MRI (bpMRI). This framework introduces several key innovations that set it apart from prior work. 1) First, we developed a multi-scale foundation model trained on a large dataset of single-year bpMRI scans, comprising 5,162 cases from 10 institutions. This model was designed to handle follow-up tasks where data availability is limited. The multi-scale design enables the model to effectively process information at both the full bpMRI scan level and the lesion Region of Interest (ROI) level. 2) Second, we incorporated a transformer-based architecture into the framework. This architecture processes 2D inputs at the full bpMRI scan level while functioning as a sequential-3D model at the lesion level. By combining the strengths of 3D modeling for detailed lesion analysis with the computational efficiency of 2D processing, the framework minimizes processing time while maintaining high-resolution insights into lesion characteristics. 3) Third, the framework integrates longitudinal data by combining deep features extracted from lesion patches in both prior and current-year bpMRI scans. This approach enables the model to detect lesion progression over time, resulting in enhanced performance compared to methods that rely on single-year data alone. 4) Finally, our framework outperformed both clinical radiologists and a Res-UNet-based PCa diagnosis model. These results underscore its potential to advance PCa progression detection in AS protocols, providing an accurate, efficient, and clinically meaningful tool for managing patients undergoing AS.




Figure 1: Schematic diagram of our PCa progression detection framework. The yellow blocks represent the network components trained within this module, while the blue blocks indicate network components with weights from the previous step.

2. Methods

As illustrated in Figure 1, our PCa progression prediction framework is composed of three key modules: a lesion detection module, a lesion classification module, and a multi-scan lesion progression prediction module. The lesion detection module identifies potential lesions across the full bpMRI scans, while the lesion classification and progression prediction modules focus on analyzing each detected lesion region in greater detail.

2.1. Multi-scale foundation model

Given the unique challenges of progression prediction in AS, data availability and direct supervised training for progression remain constrained. In this study, while a large volume of single-year bpMRI scans is available, only a relatively small subset contains annotated PCa lesions, and longitudinal bpMRI scans are extremely limited. To address these challenges, we first developed a multi-scale foundational model using a self-supervised learning framework. This foundational model is then integrated into the supervised modules of our PCa progression prediction framework, leveraging the limited cases with lesion annotations and the very small number of longitudinal bpMRI scans.

2.1.1. Model structure and self-supervised learning approach

Our self-supervised model utilizes an encoder-decoder architecture, where the encoder functions as the foundational model, and the decoder assists in training the encoder but is discarded once training is completed. For the core network block, we adopted the Vision Transformer (ViT) structure (Dosovitskiy, 2020). To tailor the model to the specifics of our problem and the available dataset, we customized a ViT-tiny architecture with 12 transformer blocks in the encoder, each containing 3 attention heads. The patch size was set to 16×16 , with an output dimension of 64 for each patch.

During training, the original 2D bpMRI scans undergo a series of random transformations, including non-linear local pixel value adjustments, inner/outer cutouts (Zhou et al., 2021), and random patch dropping (He et al., 2022), to generate degraded images. This combination of local and patch-level modifications ensures the model learns meaningful and robust features through self-supervised tasks. The degraded images are processed by the ViT-tiny encoder, followed by a 3-block transformer decoder (He et al., 2022), which reconstructs the original images.

2.1.2. Multi-scale inputs

In the PCa progression prediction framework, the models must process bpMRI scans at both the full scale to detect lesions and at the local scale to analyze lesion Regions of Interest (ROIs). Both scales rely on the foundation model to effectively leverage the large volume of single-year bpMRI scans for enhanced feature extraction and analysis. To achieve this, we developed a multi-scale training method that enables the foundation model to handle variable image sizes.

Initially, the foundation model is trained on full-scale bpMRI scans (240×240 pixels), as outlined in Section 2.1.1. Following this, the model undergoes additional training on cropped bpMRI patches (64×64 pixels) generated by the case-level lesion detection module, as detailed in Section 2.2. To support this process, we modified the positional embedding strategy by retaining the relative positional encoding from the full scan for each patch. This adjustment provides the model with spatial context, helping it understand each patch's location relative to the entire bpMRI scan and enhancing its ability to analyze patch-level features within the broader scan.

2.2. Lesion detection module

Building upon the pre-trained foundation model, we integrated it with a transformer-based decoder (Cheng et al., 2022) as the segmentation head to detect potential lesion patches. This module was trained as a segmentation task, producing five pixel-wise segmentation masks corresponding to five categories: Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3 , ≥ 4 , and Gleason Score Grade Group (GGG) ≥ 1 , ≥ 2 , ≥ 3 . This design enables precise lesion detection and categorization, effectively utilizing the label information

available in our dataset. The model was optimized using a combination of binary crossentropy and the Dice Similarity Coefficient as loss functions.

Upon completion of the training process, the output from the penultimate layer for the GGG ≥ 2 label was used as a heatmap to propose clinically significant lesion areas. Each pixel value in the heatmap represents the probability of lesion presence at that specific location, indicating the associated malignancy risk. A threshold of 0.3 was applied to generate the segmentation areas. To extract lesion ROI patches, we identified the center of each segmented area and cropped a 3D lesion patch of size $80 \times 80 \times$ slides pixels. The number of slides for each lesion was kept flexible, varying based on the segmentation results.

2.3. Lesion classification module

Using the pre-trained foundation model, we integrated a 3-block transformer structure with an additional class token to perform lesion classification. The output consists of patch-level predictions for the five categories outlined in Section 2.2. Since our patches are 3D and may contain varying numbers of slices, we treated each slice as a token in a sequence, similar to variable-length sentences, as shown in Figure 1. During training, to address the variability in the size of each data point, we set the batch size to 1 and accumulated gradients over 16 mini-batches before updating the model's weights.

2.4. Multi-scan lesion progression prediction module

For longitudinal bpMRI lesion progression prediction, each 3D lesion patch is first processed by the lesion classification module. The output from the penultimate layer of the classification head is a 64-dimensional latent feature vector, representing the 3D candidate patch regardless of the number of slices it contains. Subsequently, the latent features from these patches, including lesion image patches from both the current and previous year's bpMRI scans, are passed through a one-block transformer structure with an additional class token to generate the final detection result. This design adds flexibility, allowing the framework to incorporate lesion patch information from multiple years, thus enabling the detection of lesion progression in subsequent years, such as the third or fourth year.

During training, due to the limited availability of cases with follow-up bpMRI scans, we first generated many synthetic lesion pairs. Specifically, we cropped clinically significant lesion pairs from single-year bpMRI scans and paired them with lesions from the same location but from different patients. The module was trained using these synthetic lesion pairs. Following this, we used real lesion pairs from the active surveillance dataset, where each lesion was paired with its corresponding image patches from the previous year's bpMRI scans to detect lesion progression. To ensure the patches come from the same location, the previous year's bpMRI scans were registered to the current year's scans. A 3-fold crossvalidation was employed during this step to assess the model's performance.

3. Experiments and Results

3.1. Datasets and Implementation

The data used in this study is divided into two cohorts. The first cohort consists of 5,162 cases from 10 different institutions, each containing a single-year prostate MRI examination.

The ground truth labels include both case-level and lesion-level annotations (with voxelwise lesion annotations, when applicable), along with PI-RADS scores and GGG scores. These labels are derived from radiology and biopsy reports.

The second cohort is a smaller dataset collected as part of the Miami Active Surveillance Trial at the University of Miami. It includes 206 cases diagnosed with very low to intermediate-risk PCa who chose to manage their cancer using the AS protocol. This protocol involves an MRI and biopsy with MRI targeting, followed by annual imaging and biopsies for the next three years or until AS endpoints are reached, resulting in a total of 458 single-year MRI scans. Consecutive MRI exams (previous + current) from the same cases were paired to create case pairs. For cases with three or four MRI exams, this resulted in two or three case pairs per patient. Only case pairs with radiologist-labeled lesions were included, yielding a total of 232 case pairs in this cohort. The ground truth labels for this cohort include the prostate sector locations where radiologists detected lesions, along with their respective PI-RADS scores and GGG scores from both target and systematic biopsies.

For each MRI exam, the input to our modules included bpMRI data, which comprised axial T2-weighted (T2W) acquisition, apparent diffusion coefficient (ADC) images, diffusion-weighted imaging (DWI b-2000), and binary masks of the transition zone and peripheral zone of the prostate. A detailed description of the MRI preprocessing steps can be found in the Appendix.

3.2. Evaluation Metrics and baseline models

We evaluated our framework using the second cohort, which includes multi-year bpMRI scans collected under the AS protocol. Lesion-level progression was defined as a lesion that had a biopsy GGG of 1 or lower in the previous year but increased to 2 or higher in the current year. A case pair was considered positive if it contained at least one lesion with biopsy-confirmed progression. A total of 38 lesions across 38 cases met this criterion. The performance of the models was evaluated at both the case level and the lesion level. At the case level, we calculated the Area Under the Receiver Operating Characteristic Curve (AUROC), and at the lesion level, we calculated the Alternative Free-response Receiver Operating Characteristic Curve AUC (AFROC AUC). Since the ground truth does not include the exact pixel-wise location of the lesions, a true positive was defined as the presence of a detected lesion mask that overlaps with the ground truth lesion sector.

We compared our framework against radiologists and a deep learning-based baseline model. Radiologists assigned PI-RADS scores based on both the current and previous year's bpMRI scans, so the ability of PI-RADS to indicate biopsy-confirmed lesion progression reflects the radiologists' performance. For the deep learning-based baseline model, we used a Res-UNet (Yu et al., 2020b,a), trained from scratch on the same data cohorts. Further details of this model are provided in the Appendix.

3.3. Experimental Results and Model Comparison

Figure 2 presents the main results of our PCa progression detection framework. At the lesion level (left), our method achieved an AFROC AUC of 0.667, demonstrating a significant improvement over the CNN-based model (0.599). Additionally, the PI-RADS points from radiologists fall below our curve. Out of the 38 progressed lesions, 26 were identified by radiologists and confirmed through targeted biopsy, while 14 were detected by systematic biopsy but missed by radiologists. Our framework successfully detected 12 of the 14 lesions missed by radiologists. At the case level (right), our method achieved slightly better performance (AUROC 0.727) compared to the Res-UNet model (0.720), although it remains slightly lower than radiologists' performance (0.745).




Figure 2: (Left) Lesion-level PCa progression prediction performance of our method and baseline models. "PI-RADS point 1" represents cases where radiologists identified an increase in PI-RADS score in the current year, reaching ≥ 3 and "PI-RADS point 2" reflects cases with PI-RADS scores ≥ 3 for the current year. (Right) Case-level PCa progression detection performance of our method and baseline models.

We further compared the performance of the multi-scan lesion progression prediction module with the use of only lesion patches from the current year. After incorporating multi-scan lesion patches, the lesion-level AFROC AUC improved to 0.667, up from 0.632. Figure 3 shows the lesion-level AFROC, along with two visualization examples based on T2-weighted imaging. The full bpMRI images are provided in the Appendix.

In routine clinical practice, single-year patient-level analysis is typically used to recommend biopsy testing during AS. To align with this approach, we compared the patient-level performance of our lesion detection module with the Res-UNet and radiologists. Specifically, the lesion proposal module evaluated all slices in each single-year bpMRI scan to generate a 3D heatmap. The maximum value from the 3D heatmap was defined as the patient's prediction score for comparison purposes. The results are shown in Table 1.

Table 1: Patient-level performance (AUROC) comparisons.

Model	$\text{PI-RADS} \geq 3$	$\text{PI-RADS} \geq 4$	$\mathrm{GGG} \geq 1$	$\mathrm{GGG} \geq 2$	$\mathrm{GGG} \geq 3$
Res-UNet	0.677	0.734	0.617	0.734	0.728
Radiologist	nan	nan	0.680	0.738	0.731
Our framework	0.723	0.741	0.655	0.745	0.733

We also performed ablation studies to evaluate the contributions of key components of our model. The first ablation study assesses the advantages of the multi-scale design in the




Figure 3: (Left) Lesion-level PCa progression detection performance, comparing results with and without the multi-scan lesion progression prediction module. (Right) Two T2W visualization examples where the multi-scan prediction module improves lesion progression detection.

foundation model. Without this setting, the lesion classification module would need to be trained from scratch, resulting in a decrease in the final lesion-level AFROC to 0.546. The second ablation study investigates the benefits of using a sequential-3D approach at the lesion level. When the commonly employed 2D method was applied—where the maximum score from individual 2D slices was used to determine the score for the 3D lesion—the lesion-level AFROC dropped to 0.609, highlighting the advantages of the sequential-3D approach. A summary of the results is provided in Table 2.

Table 2: Lesion-level performance (AFROC AUC) comparisons for ablation studies.

	Full framework	w/o Multi-scan	w/o sequential-3D	w/o Multi-scale
Our Framework	0.667	0.632	0.609	0.546

4. Conclusion

This paper presents a PCa progression prediction framework for AS protocols. The approach utilizes a large cohort of single-year prostate bpMRI scans to train a multi-scale foundational model, which is then applied to task-specific modules within the framework. By incorporating longitudinal bpMRI scans, the framework significantly improves lesion progression detection compared to baseline models. Our framework demonstrates the potential for generalization to the management of other diseases requiring continuous monitoring, especially in cases where longitudinal datasets are limited, but single-time-point routine examination data are abundant. **Disclaimer** The concepts and information presented in this paper are based on research results that are not commercially available. Future commercial availability cannot be guaranteed.

ProstateAI Clinical Collaborators Dr. Henkjan Huisman⁵, Dr. Angela Tong⁶, Dr. David Winkel⁷, Dr. Tobias Penzkofer⁸, Dr. Ivan Shabunin⁹, Dr. Moon Hyung Choi¹⁰, Dr. Qingsong Yang¹¹, Dr. Dieter Szolar¹², Dr. Steven Shea¹³, Dr. Fergus Coakley¹⁴, Dr. Mukesh Harisinghani¹⁵

⁵ Radboud University Medical Center; ⁶ New York University, New York City, NY, USA; ⁷ Universitätsspital Basel, Basel, Switzerland; ⁸ Charité, Universitätsmedizin Berlin, Berlin, Germany; ⁹ Patero Clinic, Moscow, Russia; ¹⁰ Eunpyeong St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea; ¹¹ Radiology Department, Changhai Hospital of Shanghai; ¹² Diagnostikum Graz Süd-West, Graz, Austria; ¹³ Department of Radiology, Loyola University Medical Center, Maywood, IL, USA; ¹⁴ Diagnostic Radiology, School of Medicine, Oregon Health and Science University, Portland, OR, USA; ¹⁵ Massachusetts General Hospital, Boston, MA, USA.

Acknowledgments

We thank Nachiketh Soodana Prakash from the University of Miami, Miller School of Medicine, for his valuable assistance in organizing, collecting, and curating the dataset from the Miami Active Surveillance Trial.

References

- Ari Adamy, David S Yee, Kazuhito Matsushita, Alexandra Maschino, Angel Cronin, Andrew Vickers, Bertrand Guillonneau, Peter T Scardino, and James A Eastham. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. *The Journal of urology*, 185(2): 477–482, 2011.
- Michael Baboudjian, Alberto Breda, Pawel Rajwa, Andrea Gallioli, Bastien Gondran-Tellier, Francesco Sanguedolce, Paolo Verri, Pietro Diana, Angelo Territo, Cyrille Bastide, et al. Active surveillance for intermediate-risk prostate cancer: a systematic review, metaanalysis, and metaregression. *European Urology Oncology*, 5(6):617–627, 2022.
- Vilma Bozgo, Christian Roest, Inge van Oort, Derya Yakar, Henkjan Huisman, and Maarten de Rooij. Prostate mri and artificial intelligence during active surveillance: should we jump on the bandwagon? *European Radiology*, 34(12):7698–7704, 2024.
- Bowen Cheng, Ishan Misra, Alexander G Schwing, Alexander Kirillov, and Rohit Girdhar. Masked-attention mask transformer for universal image segmentation. In *Proceedings of the IEEE/CVF conference on computer vision and pattern recognition*, pages 1290–1299, 2022.

- Marc A Dall'Era and Christopher P Evans. The economics of active surveillance for prostate cancer. Active Surveillance for Localized Prostate Cancer: A New Paradigm for Clinical Management, pages 179–185, 2012.
- Coen De Vente, Pieter Vos, Matin Hosseinzadeh, Josien Pluim, and Mitko Veta. Deep learning regression for prostate cancer detection and grading in bi-parametric mri. *IEEE Transactions on Biomedical Engineering*, 68(2):374–383, 2020.
- Alexey Dosovitskiy. An image is worth 16x16 words: Transformers for image recognition at scale. arXiv preprint arXiv:2010.11929, 2020.
- Kaiming He, Xinlei Chen, Saining Xie, Yanghao Li, Piotr Dollár, and Ross Girshick. Masked autoencoders are scalable vision learners. In *Proceedings of the IEEE/CVF conference* on computer vision and pattern recognition, pages 16000–16009, 2022.
- Owain T Jones, Natalia Calanzani, Smiji Saji, Stephen W Duffy, Jon Emery, Willie Hamilton, Hardeep Singh, Niek J de Wit, and Fiona M Walter. Artificial intelligence techniques that may be applied to primary care data to facilitate earlier diagnosis of cancer: systematic review. *Journal of Medical Internet Research*, 23(3):e23483, 2021.
- Netty Kinsella, Jozien Helleman, Sophie Bruinsma, Sigrid Carlsson, Declan Cahill, Christian Brown, and Mieke Van Hemelrijck. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. *Translational andrology and urology*, 7(1): 83, 2018.
- Changhee Lee, Alexander Light, Evgeny S Saveliev, Mihaela Van der Schaar, and Vincent J Gnanapragasam. Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer. *NPJ digital medicine*, 5(1):110, 2022.
- M Dror Michaelson, Shane E Cotter, Patricio C Gargollo, Anthony L Zietman, Douglas M Dahl, and Matthew R Smith. Management of complications of prostate cancer treatment. *CA: a cancer journal for clinicians*, 58(4):196–213, 2008.
- Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle, and Ahmedin Jemal. Cancer statistics, 2023. CA: a cancer journal for clinicians, 73(1):17–48, 2023.
- Nikita Sushentsev, Leonardo Rundo, Oleg Blyuss, Vincent J Gnanapragasam, Evis Sala, and Tristan Barrett. Mri-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. *Scientific Reports*, 11(1):12917, 2021.
- Nikita Sushentsev, Leonardo Rundo, Luis Abrego, Zonglun Li, Tatiana Nazarenko, Anne Y Warren, Vincent J Gnanapragasam, Evis Sala, Alexey Zaikin, Tristan Barrett, et al. Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. *European Radiology*, 33(6):3792–3800, 2023.
- Anirudh Tomer, Daan Nieboer, Monique J Roobol, Anders Bjartell, Ewout W Steyerberg, Dimitris Rizopoulos, Movember Foundation's Global Action Plan Prostate Cancer Active

Surveillance (GAP3) consortium, Bruce Trock, Behfar Ehdaie, Peter Carroll, et al. Personalised biopsy schedules based on risk of gleason upgrading for patients with low-risk prostate cancer on active surveillance. *BJU international*, 127(1):96–107, 2021.

- Jeffrey J Tosoian, Mufaddal Mamawala, Jonathan I Epstein, Patricia Landis, Sacha Wolf, Bruce J Trock, and H Ballentine Carter. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. *Journal of Clinical Oncology*, 33(30):3379–3385, 2015.
- Xin Yu, Bin Lou, Bibo Shi, David Winkel, Nacim Arrahmane, Mamadou Diallo, Tongbai Meng, Heinrich Von Busch, Robert Grimm, Berthold Kiefer, et al. False positive reduction using multiscale contextual features for prostate cancer detection in multi-parametric mri scans. In 2020 IEEE 17th international symposium on biomedical imaging (ISBI), pages 1355–1359. IEEE, 2020a.
- Xin Yu, Bin Lou, Donghao Zhang, David Winkel, Nacim Arrahmane, Mamadou Diallo, Tongbai Meng, Heinrich von Busch, Robert Grimm, Berthold Kiefer, et al. Deep attentive panoptic model for prostate cancer detection using biparametric mri scans. In Medical Image Computing and Computer Assisted Intervention-MICCAI 2020: 23rd International Conference, Lima, Peru, October 4–8, 2020, Proceedings, Part IV 23, pages 594–604. Springer, 2020b.
- Zongwei Zhou, Vatsal Sodha, Jiaxuan Pang, Michael B Gotway, and Jianming Liang. Models genesis. *Medical image analysis*, 67:101840, 2021.

Appendix A. Preprocessing of MRI

Initially, the original T2-weighted (T2W) and diffusion-weighted imaging (DWI) series were extracted from the raw DICOM files. For DWI, both the Apparent Diffusion Coefficient (ADC), a semi-quantitative parametric map derived from multiple DWI sequences with varying b-values, and calculated DWI b-2000 images were utilized. The ADC and DWI b-2000 images were registered to their corresponding T2W series and resampled to a voxel spacing of 0.5 mm \times 0.5 mm in the axial plane while maintaining the original resolution along the slice axis. All images were normalized to facilitate the training process. T2W images were linearly normalized to the range [0,1] based on the 0.05 and 99.5 percentiles of pixel intensity. Since ADC volumes represent quantitative parametric maps, they were normalized using a constant factor of 3000. For the DWI b-2000 volumes, we first normalized the median intensity within the prostate gland region of the corresponding DWI b-0 volumes and then applied a constant value to linearly map the intensity range to [0, 1].

Appendix B. Baseline Deep-learning Model

We used the 2D Res-UNet model proposed in (Yu et al., 2020b,a), which includes a PCa detection model followed by a false-positive reduction model, as the baseline for comparison. The preprocessed T2W, ADC, DWI b-2000 images, and the binary prostate mask were concatenated as input to the network. The network was trained using the first cohort, which is similar to our method. During training, we applied both binary cross-entropy (BCE) loss and Dice loss.

Appendix C. Visualization Examples of Multi-Scan Setting on Lesion Progression Detection

Figure 4 presents two visualization examples where the multi-scan setting notably enhances lesion progression detection performance. In both cases, our proposed model accurately identifies lesions that progress after one year. In the first example, the lesion exhibits an increased PI-RADS score, with the patient's predicted progression probability rising from 0.46 when using a single scan to 0.78 under the multi-scan setting. In the second example, the lesion maintains a stable PI-RADS score without any reported progression, and the predicted progression probability increases from 0.52 to 0.91 under the multi-scan setting.




Figure 4: Two bpMRI visualization examples where the multi-scan prediction module improves lesion progression detection.

WANG LOU VON BUSCH GRIMM PUNNEN COMANICIU KAMEN COLLABORATORS